BioNTech SE reiterated revenue guidance for the full year 2024. For the period, Company expects revenues to be in the range of ?2.5 billion to ?3.1 billion.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
84.64 USD | -1.44% |
|
-8.08% | -19.80% |
Jun. 18 | US FDA Places Partial Clinical Hold on BioNTech's Cancer Drug Trial | MT |
Jun. 17 | Sector Update: Health Care Stocks Ease in Afternoon Trading | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-19.80% | 20.43B | |
+15.19% | 121B | |
+19.91% | 114B | |
-16.19% | 16.55B | |
-13.45% | 16.45B | |
-44.35% | 15.59B | |
+66.67% | 15.19B | |
+2.13% | 13.54B | |
+119.39% | 10.96B | |
+19.33% | 8.15B |
- Stock Market
- Equities
- BNTX Stock
- News BioNTech SE
- BioNTech SE Reiterates Revenue Guidance for the Full Year 2024